Stay updated on Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedThe record history now includes a new Revision: v3.6.6 entry, and the previous Revision: v3.6.5 entry was removed from the list.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedNewest history entry shows Revision: v3.6.5 in the version list. This change is a small metadata update to the study record.SummaryDifference0.1%

- Check49 days agoChange DetectedNew revision entry added: v3.6.4 replaces v3.6.3 in the history. This reflects an update to the record's version history without changing content or study details.SummaryDifference0.1%

- Check70 days agoChange DetectedThe revision history now lists the latest revision as v3.6.3, replacing the previous v3.6.2. This reflects an update to the version trail in the study record history.SummaryDifference0.1%

- Check77 days agoChange DetectedThe record history shows a new revision entry, updating from v3.6.0 to v3.6.2 to reflect a software version change on the page.SummaryDifference0.1%

- Check92 days agoChange DetectedRecruitment status is updated to indicate that no more participants are being sought. A new revision (v3.6.0) has been added, while the earlier revision (v3.5.5) has been removed.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.